



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/759,207	01/16/2001	Iris Pecker	00/21505	1817

7590 01/14/2002

G. E. EHRLICH (1995) LTD.
c/o ANTHONY CASTORINA
SUITE 207
2001 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202

EXAMINER

DECLoux, AMY M

ART UNIT PAPER NUMBER

1644

DATE MAILED: 01/14/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Intervi w Summary

Application No.
09/759,207

Applicant(s)
Pecker et al.

Examiner
DeCloux, Amy

Group Art Unit
1644



All participants (applicant, applicant's representative, PTO personnel):

(1) DeCloux, Amy

(3) Dr. Erlich

(2) Sheinbein Sol

(4) Dr. Pecker

Date of Interview Jan 10, 2002

Dr. Melamed

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy is given to 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No. If yes, brief description:

Claim(s) discussed: all pending

Identification of prior art discussed:
wo 91/19197

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) N/A

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

Applicants contended that they should be entitled to claim an antibody specifically binding at least one epitope of a heparanase protein, and not be limited to the human heparanase protein with the amino acid sequence of SEQ ID NO:1 disclosed in the instant application, because there is only one known human heparanase protein, and because someone could design around such a limited set of claims by mutating a few amino acids of SEQ ID NO:1. The examiner's position is that the specification has to provide adequate written support for the claims, which includes a structural basis for the protein's activity to which the claimed antibody binds, and that the instant specification provides insufficient description for an antibody to any heparanase protein, known or unknown, other than that with the amino acid sequence of SEQ ID NO:1. The examiner also pointed out that in the office often considers claims which recite 95% identity to a disclosed sequence in combination with a functional limitation. Applicants also contend WO 91/19197 is not enabled.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview (if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Amy DeCloux 1/10/02